Mr. Rhatigan is the CEO of Merz North America, leading the company strategy and operations across the United States and Canada.
Mr. Rhatigan holds a proven track record of successful business leadership, building strong teams and developing leading brands in the medical aesthetics arena. Prior to joining Merz in 2017, Mr. Rhatigan spent 17 years at Allergan where he completed his tenure as SVP, GM and chief executive of SkinMedica®.
Prior to this role, Mr. Rhatigan served as SVP of Allergan’s Facial Aesthetic business, where he led the launches and marketplace success of BOTOX® Cosmetic, JUVÉDERM® and LATISSE® in the United States.
In addition to his experience in facial aesthetics, Mr. Rhatigan has extensive leadership and product launch experience across neurosciences, medical dermatology and eye care. Prior to Allergan, Mr. Rhatigan spent nine years at Procter & Gamble in a variety of roles of increasing responsibility in sales and marketing. Mr. Rhatigan most recently served as president and chief operating officer at Alphaeon, a medical aesthetics startup company.
Mr. Rhatigan was named the “Top Aesthetics CEO” by Aesthetic Everything in 2017. Previous awards include: “Innovator in Dermatology” by the Cosmetic Surgery Forum in 2013, “Top 25 DTC Marketer” from DTC Perspectives in 2008, and “Excellence in Sales Leadership” from PDI in 2004.
Mr. Rhatigan is a member of Merz’s Global Management Board, in addition to the boards for the North American business.
Chief Commercial Officer
Mr. Urban is the chief commercial officer of Merz North America and leads the company in commercial strategy and development of the aesthetics organization.
Mr. Urban is committed to driving commercial success by taking ownership of the customer experience and leading the aesthetics team to deliver trusted results. He is a visionary leader and sales professional with more than 20 years of experience in planning strategic campaigns, closing major accounts, mentoring field personnel to greater productivity, targeting market segments, and optimizing procedures.
Prior to joining Merz in July 2016, Mr. Urban spent seven years at Ulthera, where he held the following roles: eastern regional sales director, director of national sales, and finally, vice president of U.S. sales.
As the vice president of U.S. sales for Ulthera, Mr. Urban managed six regional sales directors and a national practice manager, overseeing all aspects of the sales division of Ulthera.
Prior to his career with Ulthera, Mr. Urban served as a national sales manager for LifeSync Corporation. In this role, he helped build and launch a market for the LifeSync Wireless ECG System in the U.S.
Mr. Urban holds a bachelor’s degree from Bloomsburg University of Pennsylvania and a master’s degree from Loyola University Maryland.
Vice President, Head of Technical Operations, Merz North America
Mr. Anderson is the vice president and head of technical operations for Wisconsin and the Merz Innovation Center (MDIC) in Mesa, Arizona.
Mr. Anderson joined Merz in 2011 as vice president, quality operations & business excellence. In his current role, he is primarily accountable for manufacturing operations, supply chain management for Merz in the U.S. and quality operations globally. He has more than 24 years of experience within the biomedical, pharmaceutical and medical device industries.
Before joining Merz, Mr. Anderson served as corporate quality director and management representative for Baxter’s global purchasing and supply chain organizations. Prior to Baxter, Mr. Anderson spent two years at Hospira (Pfizer) as corporate head of quality, biosimiliars.
Mr. Anderson holds a bachelor‘s degree in molecular biology and pre-health from the University of Wisconsin – Parkside and a master’s degree in total quality management from Marquette University. He has also been certified as a Quality Engineer, Six Sigma Green Belt and ISO Lead Auditor for Medical Devices.
President and General Manager, Merz Canada
Mr. Bennett has served as general manager of Merz Canada since 2013, with full P&L and operational responsibility for the Canadian organization.
Mr. Bennett joined Merz in 2008 during the planning phase of opening the subsidiary in Canada, and served as director of sales and marketing until 2011. From August 2011 until September 2013, Mr. Bennett served as business unit director, aesthetics.
Before joining Merz, Mr. Bennett led a successful startup company in medical dermatology. Previously he served as head of consumer products division for Canderm Pharma (acquired by Sanofi), after rising through the organization over a 13-year period. Prior to Canderm, Mr. Bennett was with Apollo Pharmaceutical for five years, serving as president and general manager of Canada operations. Mr. Bennett started his career with Ondine BioPharma as director of sales.
Mr. Bennett holds a bachelor’s degree in economics from Wilfrid Laurier University.
Chief Compliance Officer
Ms. Church serves as chief compliance officer of Merz North America and global compliance officer for the Merz Group of Companies.
Ms. Church has been with Merz since 2009. She held various roles in the legal department until 2012 when she was appointed to lead the newly created compliance department. In this role, she is responsible for strategic and operational leadership to Merz on matters relating to compliance issues, including developing, monitoring and training on compliance with state and federal regulations that apply to all life sciences companies. She assumed responsibility for global compliance in 2015.
Before joing Merz, Ms. Church was executive vice president and general counsel of Connetics Corporation, a medical dermatology company that was acquired by Stiefel in 2008. Prior to her career with Stiefel, she served as general counsel of VISX, Inc., a medical device company that pioneered the vision treatment known as LASIK.
Ms. Church holds a bachelor’s degree from Duke University and a law degree from New York University. She is a member of the Merz Pharma Board, the management group for the Merz Companies.
Vice President, CORE Services
Ms. Coelho joined Merz in November 2009 and currently serves as vice president of CORE services. As part of CORE services, Ms. Coelho leads the following departments: corporate communications, commercial analytics, fleet and facilities operations, meeting and events, human resources, organizational development, leadership development, and production, media & design.
She has more than 28 years of experience in the healthcare industry, with more than 15 of those years focused on sales leadership, commercial operations and human resources in specialty pharmaceuticals.
Prior to joining Merz, Ms. Coelho spent nine years at Johnson and Johnson in various sales leadership roles of increasing responsibility. Prior to her career in specialty pharmaceuticals, she held various management roles with Marriott Healthcare Services.
Ms. Coelho holds a master’s degree in pharmaceutical marketing from St. Joseph’s University and a bachelor’s degree from the University of South Carolina.
Vice President, Research and Development, Merz North America
Mr. Dobrowski is the VP of Research and Development (R&D) at Merz North America and leads the company in R&D across the United States.
Mr. Dobrowski is an accomplished, strategic and diverse R&D executive with over 25 years of pharmaceutical and medical device development experience. He has had repeated success with bringing innovative products through development and into the marketplace across multiple therapeutic classes. Mr. Dobrowski has successfully built R&D organizations and demonstrated a proven ability to execute a clear vision for R&D. He has obtained multiple new product approvals from the FDA for both drugs and devices.
Prior to joining Merz, Mr. Dobrowski served as director of regulatory affairs and medical writing at Salix Pharmaceuticals, where he led regulatory affairs and medical writing to successful FDA approvals of Xifaxan and Apriso. In addition, Mr. Dobrowski spent three years at UCB/Schwarz as the director of regulatory affairs where he was responsible for Schwarz‘s first NCE eCTD NDA submission and FDA approval (Neupro®).
In addition to his experience in R&D, Mr. Dobrowski has extensive leadership expertise in R&D and medical affairs, leading strategies and activities across the entire portfolio of aesthetics and neuroscience.
Mr. Dobrowski is a member of Merz’s Global R&D Leadership Team and the Merz North America Leadership Team.
Bill Edwards, JD
Vice President, General Counsel & Secretary, Merz North America
Mr. Edwards is vice president, general counsel and secretary of Merz North America and provides legal counsel on North American operations and business strategy.
Mr. Edwards is responsible for leading the ongoing operations of the North American legal function and for advising management using a solution-oriented approach to address legal challenges and facilitate execution of the company’s business strategy. He collaborates with global colleagues in providing legal counsel and support for North American business development initiatives, including product development, acquisition and licensing arrangments, and aligns the focus of the North American legal function with global strategies.
Mr. Edwards’ life sciences experience spans over 20 years serving as in-house counsel. He has extensive and diverse experience across the pharma and medical device industries, including biologics and cosmetic products.
Prior to this role, Mr. Edwards served as assistant general counsel at GlaxoSmithKline where he provided legal counsel on numerous facets of GSK’s commercial business operations, including regulatory compliance, government financed and managed healthcare, FDA regulation of product promotion and development, business planning and risk management. He also served as director of public policy in GSK corproate affairs and was active in legislative advocacy and grass roots initiatives.
Prior to GSK, Mr. Edwards practiced for seven years at Smith Helms Mulliss & Moore, LLP, representing hospitals, healthcare systems and healcare professionals on corporate, regulatory, reimbursement, financing and risk management.
Vice President of Marketing, Aesthetics
Mr. Gumus is the vice president of marketing, aesthetics. In this role, he leads the portfolio and brand marketing strategies to help MNA achieve its commercial targets and support Merz’s vision to become the most admired, trusted and innovative company for customers.
Mr. Gumus has a strong track record in the aesthetics space and is one of the key employees Merz retained from the 2010 acquisition of BioForm Medical, Inc., to execute the company’s aesthetics strategy.
In his previous role as head of global marketing aesthetics, Mr. Gumus led teams in Frankfurt, Geneva and Mesa to successfully execute a number of campaigns and events, strengthen the pipeline, and reorganize the business to better collaborate with all four regional commercial functions. He has also served as the general manager for Merz in France, where he successfully grew revenues and transformed the business into sustained profitability.
Before joining Merz, Mr. Gumus was the director of business development and investor relations at BioForm where he was responsible for investor relations, new business acquisitions and a variety of other sales and marketing initiatives. Mr. Gumus was a member of the initial public offering (IPO) team and played an active role in the ultimate sale of BioForm to Merz.
Mr. Gumus holds a bachelor’s degree from Johns Hopkins University.
Vice President, Neurosciences
Mr. O’Brien joined Merz in August 2017 as vice president of the neurosciences division. In this role, he is responsible for leading the commercial strategy and execution for the business, including oversight of field sales, managed markets and marketing in North America.
Mr. O’Brien is a global healthcare executive with over 25 years of experience in sales, sales leadership and business development in the U.S., Canada and Asia Pacific. Prior to joining Merz, he spent 16 years with Allergan in the dermatology and aesthetics fields. Mr O‘Brien spent six years on international assignments – his most recent in Canada as the executive director of medical aesthetics. Prior to that, he served as director of business development, medical aesthetics for Asia Pacific, based in Singapore, with a focus on China, Japan, and Korea.
Before joining Allergan, Mr. O’Brien had a successful career with J&J and Boston Scientific, in both sales and marketing functions.
Mr. O’Brien holds a bachelor’s degree from Saint Mary’s College of California and a law degree from Western State University.
Lisa D. Parr, Pharm.D.
Vice President, Research and Development, Merz Device Innovation Center
Dr. Parr is the vice president and head of research and development (R&D) for the Merz Innovation Center (MDIC) in Mesa, Arizona. Prior to coming to MDIC, Dr. Parr was based in Germany, holding the position of vice president, head of R&D filler and medical devices.
Dr. Parr has a long-standing track record of leading successful research programs, and winning regulatory strategies for leading global medical device, consumer products and pharmaceutical companies.
Prior to joining Merz, Dr. Parr was vice president, regulatory and clinical affairs at Solta Medical, where she invigorated the clinical development and regulatory strategies for Thermage, Fraxel, VASERlipo and Clear & Brilliant.
Dr. Parr has also held R&D leadership roles at Tria Beauty and Obagi Medical Products involving aesthetic innovation, and at Allergan, Boehringer Ingelheim and Bayer, involving therapeutic-based development programs.
Dr. Parr holds a bachelor’s degree in pharmacy from the University of Pittsburgh and a doctorate in pharmacy from the University of Illinois at Chicago.
Vice President, Skincare Sales and Integrated Customer Experience
Dr. Parrish serves as vice president, skincare sales and integrated customer experience. In this role, he leads the skincare (NEOCutis), asclera and inside sales teams, as well as Merz’s customer service and project management functions.
Since joining Merz in 2009, Dr. Parrish has worked in a variety of sales, marketing and business/corporate devlopment roles, including an international assignment at Merz’s headquarters located in Frankfurt, Germany.
Prior to joining Merz, Dr. Parrish was a consulant at Navigant Consulting (formerly Easton Associates) and a research scientist at Cephalong, Inc. (has since been acquired by Teva Ltd.).
Dr. Parrish holds a master’s degree from Cornell University and a doctorate in organic chemistry from the University of California, Santa Barbara.
Terri L. Phillips, M.D.
Vice President and Head of Global Medical Affairs
Terri L. Phillips, M.D., joined Merz in January 2018 as Vice President and Head of Global Medical Affairs. In this role, she oversees the medical affairs function for the company’s two businesses in medical aesthetics and neurosciences.
Dr. Phillips is widely recognized for her scientific, technical and business innovation expertise and has been in the pharmaceutical industry for more than 15 years. Prior to joining Merz, Dr. Phillips served as Vice President of Global Medical Affairs at Santen where she was responsible for organizational design and build up for the company’s first global medical affairs function. She also worked at Allergan for nine years, assuming increasingly expanded leadership roles.
Dr. Phillips holds a bachelor’s degree from Bennett College and a doctor of medicine degree from Morehouse School of Medicine in Atlanta. She is dual board certified in neonatal/prenatal medicine and pediatrics.
Vice President, Financial Planning, Analysis and Operational Excellence
Ms. Ramanna is the VP of financial planning, analysis and operational excellence at Merz North America. In this role, she leads the controlling, commercial analytics and project management functions. She is focused on reinforcing data-driven decision making through the company and driving operational efficiency through strategic projects.
Prior to coming to Merz North America, Ms. Ramanna was based in Gemany where she worked with the global CEO to manage board and shareholder relations, and implement global strategic initiatives.
Ms. Ramanna spent three years at Ulthera where she served on the senior management team and led strategic planning, finance and commercial excellence funtions. She was actively involved in corporate development activities, including the acquisition of Cabochon (Cellfina) by Ulthera and the ultimate sale of Ulthera to Merz.
Prior to Ulthera, Ms. Ramanna worked at Amadeus Capital Partners, a London based venture capital firm, where she served as the firm’s resident medical technology expert. Over her 17-year career she has gained cross functional experience in R&D, commercial operations and finance.
Ms. Ramanna holds a master’s degree in molecular genetics from Rutgers University and a master’s degree in business administration from London Business School.
Global Head, IT and Sourcing
Dr. Schacht serves as the global head, IT and sourcing for Merz, including Merz North America.
Dr. Schacht joined Merz in 2007 to establish the global strategic sourcing division. He was instrumental in the global implementation of lean management in 2010 and served as lean management officer for three years, in addition to his role as chief purchasing officer.
Since 2013, Dr. Schacht has served as head of corporate IT (CIO), in addition to head of corporate strategic sourcing (CPO).
Dr. Schacht brings 16 years of industry experience to his role and is a member of the North America Leadership Team.
Dr. Schacht holds a bachelor’s degree from the University of Frankfurt in Germany and a master’s degree from the University of Santa Barbara in California.